Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.39) by 27.27 percent. This is a 49.09 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $2.262 thousand which missed the analyst consensus estimate of $9.750 thousand by 76.80 percent. This is a 94.57 percent decrease over sales of $41.691 thousand the same period last year.